Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 24;14(21):5214.
doi: 10.3390/cancers14215214.

Is Lymphocyte C-Reactive Protein Ratio Useful for Predicting Survival in Patients with Non-Metastatic Soft Tissue Sarcoma?

Affiliations

Is Lymphocyte C-Reactive Protein Ratio Useful for Predicting Survival in Patients with Non-Metastatic Soft Tissue Sarcoma?

Tomoki Nakamura et al. Cancers (Basel). .

Abstract

Background: Recently, the lymphocyte-to-CRP ratio (LCR) was found to have a prognostic role in many cancers. However, the clinical significance of LCR in patients with soft tissue sarcoma (STS) has not yet been established. This study aimed to determine whether LCR can predict disease-specific survival (DSS) and event-free survival (EFS) in patients with STS. Methods: In this study, 132 patients were enrolled. The mean follow-up periods were 76.5 months. Blood examinations were performed prior to treatment for all patients. Results: The 5-year DSS in patients with higher and lower LCR was 86.5% and 52.8%, respectively (p < 0.001). Patients with lower LCR had worse survival than those with higher LCR. The 5-year EFS in patients with higher and lower LCR was 66.2% and 31.2%, respectively (p < 0.001). On Receiver operating characteristic analysis, however, there was no significant difference in the area under curve (AUC) between CRP level (AUC = 0.72) and LCR (AUC = 0.711). Conclusions: LCR may be a prognostic factor for predicting oncological events in multivariate analysis, although ROC analysis could not show the superiority of LCR to CRP for predicting oncological outcomes in patients with STS.

Keywords: lymphocyte- to- C-reactive protein ratio; soft tissue sarcoma; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier curves showing disease-specific survival. A: Patients with a higher lymphocyte-to-C-reactive protein ratio. B: Patients with a lower lymphocyte-to-C-reactive protein ratio.
Figure 2
Figure 2
Kaplan–Meier curves showing event-free survival. A: Patients with a higher lymphocyte-to-C-reactive protein ratio; B: Patients with a lower lymphocyte-to-C-reactive protein ratio.
Figure 3
Figure 3
Receiver operating characteristic curve showing significant difference in area under the curve between absolute lymphocyte count (solid line) and lymphocyte-to-C-reactive protein ratio (dotted line).
Figure 4
Figure 4
Receiver operating characteristic curve showing no significant difference in area under the curve between C-reactive protein level (solid line) and lymphocyte-to-C-reactive protein ratio (dotted line).

Similar articles

Cited by

References

    1. Clark M.A., Fisher C., Judson I., Thomas J.M. Soft-Tissue Sarcomas in Adults. N. Engl. J. Med. 2005;353:701–711. doi: 10.1056/NEJMra041866. - DOI - PubMed
    1. Gunar K.Z., Matthew T.B., Peter W.T., Raphael E.P., Shreyaskumar R.P., Robert S.B., Harry L.E. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy. Cancer. 2003;97:2530–2543. doi: 10.1002/cncr.11365. - DOI - PubMed
    1. Nakamura T., Asanuma K., Takao M., Yamanaka T., Koike H., Chen-Yoshikawa T.F., Tsukushi S., Kuroda H., Kozawa E., Sano M., et al. Clinical Outcome in Soft Tissue Sarcoma Patients with Lung Metastasis Who Received Metastasectomy and/or Radiofrequency Ablation: Tokai Musculoskeletal Oncology Consortium Study. Cancer Manag. Res. 2021;13:8473–8480. doi: 10.2147/CMAR.S333721. - DOI - PMC - PubMed
    1. Wang X., Liu S., Zhao X., Fang E., Zhao X. The value of C-reactive protein as an independent prognostic indicator for disease-specific survival in patients with soft tissue sarcoma: A meta-analysis. PLoS ONE. 2019;14:e0219215. doi: 10.1371/journal.pone.0219215. - DOI - PMC - PubMed
    1. Nakamura T., Matsumine A., Matsubara T., Asanuma K., Uchida A., Sudo A. Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma. Cancer. 2011;118:1055–1061. doi: 10.1002/cncr.26353. - DOI - PubMed